文献速递临床试验与 GCP真实世界研究与卫生经济

减重降低超重和肥胖乳腺癌患者癌症相关疲劳的III期随机试验:MEDEA研究设计

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.
PubMed 文献 · Trials · 2022-03-04

MEDEA是一项多中心随机对照试验,纳入220例I-III期乳腺癌、BMI≥25 kg/m²、初次治疗后12个月内、能步行≥400米的超重或肥胖幸存者,1:1随机分为单纯健康教育组与个性化电话减重干预联合健康教育组,主要终点为12个月时EORTC QLQ-C30自报癌症相关疲劳组间差异,以80.0%把握度(双侧α=0.05)检测标准化效应量0.40。

要点

  • MEDEA评估减重干预对超重或肥胖乳腺癌幸存者癌症相关疲劳的影响。
  • 干预组接受24次半结构化电话减重干预联合健康教育,对照组仅接受健康教育。
  • 主要分析比较随机化后12个月两组自报癌症相关疲劳(EORTC QLQ-C30)。

核心结论

  • MEDEA将检验减重干预对超重或肥胖乳腺癌幸存者癌症相关疲劳的影响,可能提供额外管理策略并有助于将减重支持确立为新的临床照护标准。

研究设计与样本

  • 多中心随机对照试验,计划纳入220例I-III期乳腺癌、BMI≥25 kg/m²、初次治疗后12个月内、能步行≥400米的超重或肥胖幸存者。
  • 参与者按1:1随机分为单纯健康教育组与个性化电话减重干预联合健康教育组。
  • 干预组由个体生活方式教练通过1年内24次半结构化电话实施干预,基于社会认知理论并改编自Breast Cancer Weight Loss试验(BWEL,A011401)。

主要发现

  • 干预目标包括体重减轻≥基线10%、每日热量限制500-1000 Kcal、增加体力活动至150分钟/周(初始阶段)和225-300分钟/周(维持阶段)。
  • 主要终点为两组间自报癌症相关疲劳(EORTC QLQ-C30)的差异。
  • 次要终点包括生活质量(EORTC QLQ-C30、-BR45、-FA12)、焦虑和抑郁(HADS)、体重和BMI、饮食习惯和质量、体力活动、睡眠、医疗费用(住院、全部药物消耗、病假)和成本效果(每质量调整生命年成本)、患者动机和满意度。
  • 主要分析比较随机化后12个月两组自报癌症相关疲劳,以80.0%把握度(双侧α=0.05)检测标准化效应量0.40。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated body mass index (BMI) represents a risk factor for cancer-related fatigue (CRF). Weight loss interventions are feasible and safe in cancer survivors, leading to improved cardio-metabolic and quality of life (QOL) outcomes and modulating inflammatory biomarkers. Randomized data are lacking showing that a lifestyle intervention aimed at weight loss, combining improved diet, exercise, and motivational counseling, reduces CRF. Motivating to Exercise and Diet, and Educating to healthy behaviors After breast cancer (MEDEA) is a multi-center, randomized controlled trial evaluating the impact of weight loss on CRF in overweight or obese survivors of breast cancer. Herein, we described the MEDEA methodology. METHODS: Patients (N = 220) with stage I-III breast cancer and BMI ≥ 25 kg/m2, within 12 months of primary treatment, and able to walk ≥ 400 m are eligible to enroll. Participants are randomized 1:1 to health education alone vs. a personalized telephone-based weight loss intervention plus health education. Both arms receive a health education program focusing on healthy living. Patients in the intervention arm are paired with an individual lifestyle coach, who delivers the intervention through 24 semi-structured telephone calls over 1 year. Intervention goals include weight loss ≥ 10% of baseline, caloric restriction of 500-1000 Kcal/day, and increased physical activity (PA) to 150 (initial phase) and 225-300 min/week (maintenance phase). The intervention is based on the social cognitive theory and is adapted from the Breast Cancer Weight Loss trial (BWEL, A011401). The primary endpoint is the difference in self-reported CRF (EORTC QLQ-C30) between arms. Secondary endpoints include the following: QOL (EORTC QLQ-C30, -BR45, -FA12), anxiety, and depression (HADS); weight and BMI, dietary habits and quality, PA, and sleep; health care costs (hospital-admissions, all-drug consumption, sick leaves) and cost-effectiveness (cost per quality-adjusted life-year); and patient motivation and satisfaction. The primary analysis of MEDEA will compare self-reported CRF at 12 months post-randomization between arms, with 80.0% power (two-sided α = 0.05) to detect a standardized effect size of 0.40. DISCUSSION: MEDEA will test the impact of a weight loss intervention on CRF among overweight or obese BC survivors, potentially providing additional management strategies and contributing to establish weight loss support as a new standard of clinical care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04304924.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Di Meglio A, Martin E, Crane TE, et al. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. Trials. 2022. PMID: 35246219. doi:10.1186/s13063-022-06090-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。